In a previous study body fluid biomarkers for brain damage after ischemic stroke including S100B, glial fibrillary acid protein (GFAP) and ubiquitin C-terminal hydrolase (UCH-L1) were significantly lower in the EPO treated patients than in placebo treated ones (14). The gene discussed is GFAP; the disease is ischemic stroke.